6533b831fe1ef96bd1299878
RESEARCH PRODUCT
A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes
Thomas WölfelBenoît Van Den EyndeGérard DegiovanniAnnie OomsVincent BrichardAline Van PelSandra MorelPierre Van Der Bruggensubject
Cytotoxicity ImmunologicHerpesvirus 4 HumanCancer Researchmedicine.medical_treatmentAntigen presentationTyrosinase PeptideBiologyTransfectionAntigenTumor Cells CulturedmedicineAnimalsHumansCytotoxic T cellAmino Acid SequenceMelanomaPeptide sequenceAllelesCell Line TransformedB-LymphocytesMonophenol MonooxygenaseMelanomaImmunotherapymedicine.diseasePeptide FragmentsRecombinant ProteinsCTL*OncologyCOS CellsImmunologyCancer researchHLA-B35 AntigenT-Lymphocytes Cytotoxicdescription
We previously described different cytotoxic T lymphocyte (CTL) clones isolated from the blood lymphocytes of a melanoma patient after in vitro stimulation with autologous tumor cells. These CTL clones recognized at least 2 distinct antigens on the melanoma cells. Here, we show that one of them consists of a peptide derived from tyrosinase and presented by HLA-B35. The peptide is 9 amino acids long and has the sequence LPSSADVEF. It can be presented by the 2 major B35 allelic subtypes, B*3501 and B*3503. As HLA-B35 is one of the most frequent HLA-B specificities, being present in about 20% of Caucasian individuals, it may be a useful target for peptide-based immunotherapy of melanoma.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1999-12-22 | International Journal of Cancer |